1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ)

VICO.ST
Vicore Pharma Holding AB (publ)SE flagStockholm Stock Exchange
15.68
SEK
+2.18
- -
3.74BMarket Cap
Vicore Pharma Holding AB (publ)
VICO.ST
(Stockholm Stock Exchange)

Recent

price

15.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.09
0.06
0.06
0.05
0.02
- -
- -
- -
- -
- -
0.8
0.02
0.04
Revenue per Share
-0.12
1.44
-0.32
-0.46
-1.39
-0.92
-2.1
-2.63
-4.14
-3.89
-3.22
-1.23
-1.99
-1.88
Basic EPS, GAAP
- -
-1.3
-0.32
-0.58
-1.6
-1.49
-1.97
-2.2
-3.7
-4.08
-2.58
-1.21
-1.57
-1.68
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.26
0.78
0.39
-3.12
-3.87
-4.97
-4.65
-6.23
-8.91
-12.42
-12.62
-9.68
-7.42
- -
Book Value per Share
0.93
1.75
2.71
1.04
2.34
9.19
5.73
5.09
4.41
2.98
4.69
8.25
4.57
4.61
Tangible Book Value per Share
13
10
14
14
17
24
44
56
72
74
97
137
240
197
Basic Weighted Avg Shares
- -
1
1
1
1
1
- -
- -
- -
- -
- -
109
4
8
Sales/Revenue/Turnover
- -
-583.31
-540.83
-780.4
-3,022.85
-8,186.22
- -
- -
- -
- -
- -
-174.09
-11,905.82
-4,610.93
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
4
4
4
3
2
- -
- -
Depreciation Expense
-2
14
-5
-7
-24
-22
-93
-147
-296
-288
-311
-169
-477
-371
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
1,608.34
-544.05
-780.75
-2,599.89
-4,267.91
- -
- -
- -
- -
- -
-154.22
-12,509.14
-4,791.64
Profit Margin (%)
13
-2
21
1
20
213
250
280
312
223
455
1,130
1,098
909
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
40
54
82
32
58
285
322
355
383
289
455
1,129
1,095
908
Total Equity
- -
-10.41
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
223.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
251.92
-69.97
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
235
235
235
Market Capitalization
1,147
1,173
1,500

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,196
1,082
975
Cash, Cash Equivalents & STI
1,156
1,049
937
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
66
62
66
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
62.56%
37.21%
-3%
Free Cash Flow
73.57%
41.24%
127.79%
Net Income, GAAP
93.07%
48.87%
183.14%
Sales/Revenue/Turnover
- -
- -
-96.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
104
- -
- -
5
109
2025
1
2
- -
- -
4
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
-0.5
-0.54
-0.4
-1.23
2025
-0.48
-0.49
-0.54
- -
-1.99
2026
-0.39
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ALK-Abelló A/S (AKBLF)
Midatech Pharma plc (MTPH.L)
Precigen, Inc. (PGEN)
Spexis AG (PPHOF)
Anti-Microbial Savior BioteQ Co., Ltd (6864.TWO)
CRISM Therapeutics Corporation (CRTX.L)
Business
Vicore Pharma Holding AB (publ) (VICO.ST) is a clinical-stage pharmaceutical company that develops therapies targeting the angiotensin II type 2 receptor (AT2R) for severe lung diseases and related indications, including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH); its lead product, buloxibutid (C21), is a first-in-class oral small molecule AT2 receptor agonist (ATRAG) in Phase 2b trials for IPF with Orphan Drug and Fast Track designations from the FDA, while Almee comprises an investigational digital therapeutic medical device based on cognitive behavioral therapy in late-stage development for anxiety associated with pulmonary fibrosis, having received FDA Breakthrough Device Designation; the company also advances an early-stage pipeline of additional ATRAG candidates and preclinical assets for respiratory and cardiovascular conditions. Founded in 2000 and headquartered in Stockholm, Sweden, with operations primarily in Europe and North America, Vicore focuses on disease-modifying treatments for patients with limited options, leveraging collaborations such as with Alex Therapeutics AB for digital solutions in interstitial lung diseases and Emeriti Bio AB and HaLaCore Pharma AB for next-generation AT2R molecules. Recent developments include a SEK 882 million (USD 85 million) financing round in 2024 featuring a heavily oversubscribed rights issue and strategic investment from Sanofi, an exclusive license agreement with Nippon Shinyaku, FDA Fast Track designation for buloxibutid in IPF, and progression of the global Phase 2b ASPIRE trial for IPF, alongside discontinuation of the preclinical inhaled thalidomide program for IPF cough to prioritize core ATRAG initiatives.